DARE News

Latest breaking news and updates for DARE stock.

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025

How might the market react to the sentiment score of 70 and the earnings category classification in terms of short‑term trading volume and price momentum? What potential risks could arise from reliance on the 503B compounding pathway for product distribution, and how might they affect supply chain stability? How will the company's capital allocation strategy (e.g., R&D spend, commercial rollout costs) affect its balance sheet and liquidity going forward?

Earnings

14 days ago

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women’s health between promising science an...

What is the analyst consensus following the release, and how are major institutions altering their positions? Did the earnings call reveal any changes to the shareholder return policy (dividends, share buybacks, or stock‑based compensation)? How did management’s commentary address competitive threats and market share trends in the women’s‑health biopharma space?

Earnings

21 days ago